GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLA) » Definitions » Current Deferred Revenue

Estrella Immunopharma (Estrella Immunopharma) Current Deferred Revenue : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Estrella Immunopharma's current deferred revenue for the quarter that ended in Mar. 2024 was $0.00 Mil.

Estrella Immunopharma Current Deferred Revenue Historical Data

The historical data trend for Estrella Immunopharma's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma Current Deferred Revenue Chart

Estrella Immunopharma Annual Data
Trend Jun21
Current Deferred Revenue
-

Estrella Immunopharma Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Estrella Immunopharma Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Estrella Immunopharma (Estrella Immunopharma) Business Description

Traded in Other Exchanges
N/A
Address
5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608
Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma (Estrella Immunopharma) Headlines

No Headlines